Literature DB >> 2760476

Comparison of fluorochrome-labeled and 51Cr-labeled targets for natural killer cytotoxicity assay.

W G Wierda1, D S Mehr, Y B Kim.   

Abstract

An alternative method for measuring in vitro cellular cytotoxicity has been developed utilizing the carboxyfluorescein derivative 2',7'-bis(carboxyethyl)-5,6-carboxyfluorescein (BCECF) as the target cell label. Target cells labeled with the fluorescent dye are incubated with effector cells, if killing of targets occurs, BCEDF is released analogous to 51Cr release. Measurement of specific lysis in this assay is based on the direct measurement of dye retained by the remaining viable target cells using the Pandex FCA. In paired experiments we have compared the fluorochrome assay to the standard 51Cr release assay in measuring porcine natural killer cytotoxicity. The target labeling time with BCECF is 30 min as opposed to 1 h with 51Cr; and there is no significant dye reincorporation after release. The optimal target number per incubation well for the BCECF assay is 5 X 10(3) cells. In both the BCECF and 51Cr release assays, maximum percent specific lysis is reached after 3-4 h incubation. By 2 h incubation, the BCECF assay reaches the maximum seen with 51Cr and in a 4 h assay the maximum NK activity measured with BCECF labeled targets is always higher than that measured with 51Cr-labeled targets. In paired experiments, we have shown the reproducibility of the BCECF assay and that the BCECF assay measures NK enhancement by NK enhancing monoclonal antibody and inhibition by NK inhibiting monoclonal antibody as good as the 51Cr release assay, if not better. In conclusion, the BCECF assay is a reliable and reproducible measure of in vitro cellular cytotoxicity, eliminates the use of radioisotopes and is cost efficient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760476     DOI: 10.1016/0022-1759(89)90329-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  Quantitative evaluation of the growth of established cell lines on the surface of collagen, collagen composite and reconstituted basement membrane.

Authors:  M D Smith; M G Shearer; S Srivastava; R Scott; J M Courtney
Journal:  Urol Res       Date:  1992

2.  T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function.

Authors:  B Liang; S Ardestani; J J Marchalonis; R R Watson
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants.

Authors:  S Neri; E Mariani; A Meneghetti; L Cattini; A Facchini
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells.

Authors:  I Vollenweider; E Vrbka; W Fierz; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

5.  Ability of intracamerally inoculated B- and T-cell enriched allogeneic lymphocytes to enhance corneal allograft survival.

Authors:  S C She; E J Moticka
Journal:  Int Ophthalmol       Date:  1993-02       Impact factor: 2.031

Review 6.  New flow cytometric assays for monitoring cell-mediated cytotoxicity.

Authors:  Liubov Zaritskaya; Michael R Shurin; Thomas J Sayers; Anatoli M Malyguine
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

7.  An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials.

Authors:  R M Zucker; D J Adams; K W Bair; K H Elstein
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

8.  Sulfated polyanions block Chlamydia trachomatis infection of cervix-derived human epithelia.

Authors:  F R Zaretzky; R Pearce-Pratt; D M Phillips
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  A real-time killing assay to follow viral epitope presentation to CD8 T cells.

Authors:  Pauline Gourdain; Julie Boucau; Georgio Kourjian; Nicole Y Lai; Ellen Duong; Sylvie Le Gall
Journal:  J Immunol Methods       Date:  2013-09-20       Impact factor: 2.303

10.  Anti-IL-4 monoclonal antibody and IFN-gamma administration retards development of immune dysfunction and cytokine dysregulation during murine AIDS.

Authors:  Y Wang; S K Ardestani; B Liang; C Beckham; R R Watson
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.